Navigation Links
GWU consensus report outlines new approaches for evaluating benefits and risks of obesity drugs
Date:8/14/2012

WASHINGTON, D.C. The George Washington University School of Public Health and Health Services (GW) today released a report representing consensus findings from a cross-section of stakeholders that could help transform the process used to evaluate interventions to treat obesity, a public health crisis that now affects one in three adults. The report, "Obesity Drug Outcome Measures," results from a stakeholder dialogue group convened by GW that, over a period of nine months, explored why development and approval of obesity drugs have proven so difficult.

"At a time when so many Americans suffer with obesity and are faced with limited treatment options, there has been a rising call to review the emerging science on obesity to update the framework used when evaluating obesity drugs," said Christine Ferguson, J.D., Professor in the Department of Health Policy. "The FDA, under a reauthorized Prescription Drug User Fee Act, is likely to take a wider, more comprehensive look at how drugs developed to treat obesity affect how individuals with obesity feel and function. This report may help update the risk-benefit framework."

Participants in the stakeholder group all contributed to the consensus report findings and included consumer advocates, obesity experts, researchers and clinicians. Officials from the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) participated in the dialogue process, but were not asked to endorse the final report.

The consensus report outlines a series of new approaches that should be considered by the FDA when evaluating the benefits and risks of obesity drugs including:

  • Obesity affects everyone differently. Evaluating the benefits and risks of interventions should reflect the various considerations within the different categories of obesity based on feeling, functioning and health impairments.
  • Obesity drugs may provide an additional option for helping individuals who do not respond, or inadequately respond, to other interventions.
  • Potential pharmaceutical interventions should be reviewed as obesity treatments rather than weight loss agents and should be limited to only those for whom they are medically appropriate.
  • The benefit-risk evaluation of treatment with obesity drugs should extend beyond numerical weight loss to improvement in feeling and functioning.


'/>"/>
Contact: Melissa Warren
mwarren@ccapr.com
202-609-6010
Chandler Chicco Agency
Source:Eurekalert

Related medicine news :

1. Adolescents in substance abuse programs report using others med marijuana
2. Accelerated resolution therapy significantly reduces PTSD symptoms, researchers report
3. Survival rates for premature babies in high-level NICUs are better than previously reported
4. New report describes 7 essential steps toward an AIDS-free generation
5. Cost Keeps Many Americans From Good Dental Care: Report
6. Inactivity May Kill as Many Worldwide as Smoking: Report
7. Oxford University Press acquires joint ownership of Journal of Surgical Case Reports
8. Reducing Ozone Limits Would Save Lives, Report States
9. Reporting of hospital infection rates and burden of C. difficile
10. Report focuses on sustainability of infectious disease surveillance
11. 20% of U.S. Women Uninsured in 2010, Up From 15% in 2000: Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
Breaking Medicine Technology: